Tesamorelin and ipamorelin both increase growth hormone (GH) output, but their kinetics differ enough that timing around training matters for muscle protein synthesis (MPS). Tesamorelin is a GHRH analogue with a longer half-life, while ipamorelin is a ghrelin-mimetic secretagogue with a shorter pulse. The question is whether a pre- or post-workout tesamorelin dose can amplify the natural GH response to resistance exercise without flattening the pulsatile pattern that drives IGF-1 release. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
Step 1: Understand how tesamorelin differs from ipamorelin in GH kinetics
Tesamorelin (TH9507) is a synthetic 44-amino-acid peptide analogue of growth hormone-releasing hormone (GHRH). It binds the GHRH receptor on somatotrophs and increases GH pulse amplitude without changing pulse frequency (Falutz 2010). In contrast, ipamorelin is a pentapeptide that activates the ghrelin receptor (GHS-R1a), producing a shorter, sharper GH spike that returns to baseline within roughly two hours (Raun 1998). The half-life of tesamorelin after subcutaneous injection is about 26–38 minutes in healthy adults, but its effect on GH secretion persists for several hours because of sustained receptor occupancy (Ferdinandi 2007). Ipamorelin's half-life is under two hours, and its GH peak occurs around 30–45 minutes after injection (Gobburu 1999).
This kinetic difference is central to timing. A tesamorelin dose given 60–90 minutes before training will still be elevating GH during the workout, whereas an ipamorelin dose given at the same time may have already peaked. However, a longer GH elevation is not automatically better for MPS. The liver's IGF-1 response depends on integrated GH exposure over 24 hours, but acute MPS after resistance exercise is more closely tied to local mechano-growth factor and mTOR signalling than to circulating GH alone (West 2009). Whether a sustained GH elevation during training adds anything to the exercise-induced GH pulse is not established in human trials.
Step 2: Consider the natural GH response to resistance training
Resistance exercise itself triggers a GH pulse, with the magnitude depending on load, volume, and rest intervals. Heavy compound movements with 60–90 second rest periods produce the largest GH spikes, often peaking 15–30 minutes after the set ends (Kraemer 1991). This endogenous pulse is pulsatile, not continuous, and it is followed by a refractory period during which additional GHRH stimulation is less effective (Jaffe 1995). If tesamorelin is injected too close to the workout, it may overlap with the exercise-induced pulse and blunt the subsequent natural trough. That could theoretically reduce the total number of GH pulses over 24 hours, which is a known determinant of IGF-1 production (Veldhuis 2008).
One approach is to separate tesamorelin from the training window by at least 3–4 hours. For example, an evening tesamorelin dose after a morning workout avoids direct competition with the exercise pulse. But this also means the GH elevation from tesamorelin occurs during sleep, when natural GH secretion is already high. The interaction is complex. A small study in HIV patients with lipodystrophy found that tesamorelin increased IGF-1 by about 80 ng/mL after 26 weeks, but the dosing was fixed at 2 mg daily regardless of training (Falutz 2007). No published trial has compared pre-workout versus post-workout tesamorelin for MPS outcomes.
Step 3: Evaluate the evidence for ipamorelin timing around training
Ipamorelin's shorter action makes it easier to align with the post-exercise window. A single 200–300 mcg subcutaneous dose produces a GH peak within 45 minutes and returns to baseline by 2–3 hours (Gobburu 1999). If injected immediately after the last set, the ipamorelin-induced GH pulse would coincide with the natural exercise-induced pulse, potentially creating a larger combined pulse. Whether that larger pulse translates to greater MPS is unclear. In young men, exogenous GH infusion during recovery from resistance exercise did not increase myofibrillar protein synthesis beyond exercise alone, despite raising circulating GH and IGF-1 (West 2010). That finding suggests the exercise-induced GH pulse is already near the threshold for stimulating local muscle anabolism.
For ipamorelin, the more relevant comparison may be with other ghrelin mimetics. GHRP-6 has a similar mechanism but also stimulates appetite, which can be counterproductive during a cut. How to Compare Ipamorelin and GHRP-6 for Muscle Retention on GLP-1s covers the appetite and cortisol differences. Ipamorelin is more selective for GH release with less hunger effect, making it easier to time around meals and training without disrupting energy balance.
Step 4: Examine tesamorelin's effect on natural GH pulsatility
Tesamorelin increases GH pulse amplitude but does not appear to increase pulse frequency. In a 14-day study of healthy older adults, tesamorelin raised mean 24-hour GH concentrations by about 50% while preserving the normal circadian rhythm (Veldhuis 2008). The pulsatile pattern remained intact, with the largest pulses still occurring during slow-wave sleep. This is different from continuous GH infusion, which suppresses endogenous pulses and downregulates the GHRH receptor (Jaffe 1995). Because tesamorelin works through the GHRH receptor, it may be less disruptive to the negative feedback loop than exogenous GH itself.
However, the timing of the tesamorelin dose relative to the endogenous sleep-related pulse is not well studied. If tesamorelin is given at bedtime, it could augment the natural sleep pulse. If given in the morning, it creates an additional daytime pulse that may or may not affect the sleep pulse. The half-life of tesamorelin's active metabolite is short, but the GH response lasts 3–4 hours, so a morning dose would not directly interfere with the sleep pulse 12 hours later. This is a testable hypothesis, but no published trial has measured 24-hour GH profiles after different tesamorelin dosing times in athletes.
Step 5: Consider the interaction between tesamorelin and IGF-1 LR3
Some users stack tesamorelin with IGF-1 LR3 to target both GH output and direct IGF-1 receptor activation. IGF-1 LR3 has a half-life of 20–30 hours and binds IGF-binding proteins poorly, so it remains in circulation much longer than endogenous IGF-1 (Tomas 1998). If tesamorelin is timed to raise GH during the post-workout window, the liver's IGF-1 response would peak several hours later, potentially overlapping with the IGF-1 LR3. Whether this overlap enhances MPS or simply increases the risk of hypoglycaemia is not established. How to Combine Tesamorelin with IGF-1 LR3 for Muscle Density discusses the dosing and monitoring considerations for this combination.
For the purpose of timing around training, the key point is that tesamorelin's GH elevation is not the same as an acute IGF-1 spike. The liver takes time to convert GH into IGF-1, and the muscle's local IGF-1 response to loading is independent of circulating IGF-1 (West 2009). So a pre-workout tesamorelin dose is unlikely to increase MPS during the workout itself. A post-workout dose might support the later IGF-1 rise, but the clinical relevance for muscle growth is speculative.
Step 6: Review the limited head-to-head data on tesamorelin vs ipamorelin
No randomised controlled trial has directly compared tesamorelin and ipamorelin for muscle protein synthesis or body composition in healthy adults. The closest evidence comes from separate studies in different populations. Tesamorelin is approved for HIV-associated lipodystrophy, where it reduces visceral adipose tissue by about 15% over 26 weeks without significant change in lean mass (Falutz 2007). Ipamorelin has been studied mostly in animal models and small human pharmacokinetic trials, with no long-term body composition data (Raun 1998).
For athletes, the choice between the two often comes down to half-life and injection frequency. Tesamorelin is typically dosed once daily at 2 mg, while ipamorelin is dosed 2–3 times daily at 200–300 mcg. The shorter-acting ipamorelin allows more precise timing around training and meals, but it also requires more injections. How to Choose Between Ipamorelin and GHRP-6 for Muscle Retention on a Cut covers the practical aspects of multiple daily injections.
Step 7: Apply a cautious timing strategy for tesamorelin around training
Given the absence of direct evidence, any timing recommendation is provisional. A reasonable approach based on the pharmacokinetics would be to avoid injecting tesamorelin within 2 hours before or after resistance training. This separation reduces the chance of overlapping with the exercise-induced GH pulse and preserves the natural pulsatile pattern. For a morning workout, a tesamorelin dose in the early evening (around 6–8 pm) would be roughly 8–10 hours after training and 2–3 hours before the sleep-related GH pulse. For an evening workout, a morning tesamorelin dose would be separated by a similar interval.
This strategy assumes that the goal is to enhance MPS without blunting natural GH pulsatility. If the goal is primarily visceral fat reduction, timing around training is less relevant, and a fixed daily dose is standard. How to Assess Tesamorelin for Off-Season Visceral Fat Reduction discusses the fat-loss context. For muscle retention during weight loss, the combination of tesamorelin with a GLP-1 agonist is an emerging area, but the interaction with training timing has not been studied.
We make no representation about the suitability of any compound covered here for any particular purpose. The published literature does not yet answer whether timing tesamorelin around training changes MPS or preserves natural GH pulsatility better than a fixed daily schedule. Until controlled trials measure 24-hour GH profiles and muscle protein synthesis under different dosing times, the safest approach is to separate the injection from the workout by several hours and monitor IGF-1 levels if using the compound long-term.